Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 17Thoracic 4Head & Neck 3Gynecologic 2Genitourinary 2Dermatologic 2CNS 2Other solid neoplasm 1NET 1Myeloid 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × IFL protocol × Endocrine × Clear all
NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Biotheus Inc.

Phase 2 Recruiting
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡